Recent talks are about the recession, economic downturn, credit crunch and so on. However, the drug giant Pfizer made a remarkable start in 2009. It acquired its rival Big Pharma company Wyeth for about $68.0 billion in stock and cash (Marketletter February 2. This acquisition is said to be the one of the biggest in pharmaceutical history. However, would it have been better for Pfizer to have acquired Amgen instead of Wyeth? asks Shabeer Hussain, program leader, pharmaceutical and biotechnology, Healthcare Group, at Frost & Sullivan.
Behind the scene
Pfizer faces tough competition ahead from generics after the expiry of its blockbuster drug Lipitor (atorvastatin) in 2011. Lipitor, a cholesterol lowerer that generates around $13.0 billion a year, is facing patent expiration in 2011. Pfizer is set to face big challenges by 2012 not only from generics but also from investors because of the decline in R&D productivity. Although its pipeline has 200 products, there are no blockbusters to even the dent of around $30.0 billion left by the patent expiry of 13 drugs by 2014.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
A U.S. specialty biopharmaceutical company focused on dermatology, with operations centered on commercialization and late-stage development. The company is publicly listed on NYSE American under ticker PTHS.
Pfizer acquires Wyeth - what's next, Frost & Sullivan analysts comments
Recent talks are about the recession, economic downturn, credit crunch and so on. However, the drug giant Pfizer made a remarkable start in 2009. It acquired its rival Big Pharma company Wyeth for about $68.0 billion in stock and cash (Marketletter February 2. This acquisition is said to be the one of the biggest in pharmaceutical history. However, would it have been better for Pfizer to have acquired Amgen instead of Wyeth? asks Shabeer Hussain, program leader, pharmaceutical and biotechnology, Healthcare Group, at Frost & Sullivan.
Behind the scene
Pfizer faces tough competition ahead from generics after the expiry of its blockbuster drug Lipitor (atorvastatin) in 2011. Lipitor, a cholesterol lowerer that generates around $13.0 billion a year, is facing patent expiration in 2011. Pfizer is set to face big challenges by 2012 not only from generics but also from investors because of the decline in R&D productivity. Although its pipeline has 200 products, there are no blockbusters to even the dent of around $30.0 billion left by the patent expiry of 13 drugs by 2014.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
Become a subscriber
£820
Or £77 per month
Chairman, Sanofi Aventis UK
Company News Directory
Companies featured in this story
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
| Headless Content Management with Blaze